Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease
Masaaki Konishi, Hisao Ogawa(Jikei University School of Medicine), Shinya Hiramitsu(Nagoya Heart Center), Kunihiko Matsui(Kumamoto University), Kazuo Kimura(Kazan State Medical University), Kazuaki Uchiyama, Ichiro Hisatome(Tottori University), Hideaki Jinnouchi, Masako Waki(Shizuoka City Hospital), Hisao Mori, Hirokazu Kakuda, Naoki Kawai, Yoshihiko Saito(Nara Medical University), Eiichi Tokutake, Sunao Kojima(Kumamoto University), Takahiro Hayashi, Naoto Yokota, Yusuke Ohya(University of the Ryukyus), Yutaka Wakasa(Kanazawa Medical Center), Masahiro Sugawara(Japan Medical Association), Kenichi Tsujita(British Heart Foundation)
Cited by 38
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449